Longer Survival and Preserved Liver Function after Proton Beam Therapy for Patients with Unresectable Hepatocellular Carcinoma.
albumin-bilirubin score
hepatocellular carcinoma
proton beam therapy
radiofrequency ablation
transcatheter arterial chemoembolization
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
30 03 2023
30 03 2023
Historique:
received:
18
03
2023
accepted:
29
03
2023
medline:
17
5
2023
pubmed:
15
5
2023
entrez:
15
5
2023
Statut:
epublish
Résumé
Proton beam therapy (PBT) has been recently reported to achieve excellent tumor control with minimal toxicity in patients with unresectable hepatocellular carcinoma (HCC). Radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) was investigated for larger HCC. This study was designed to evaluate the therapeutic effect of PBT on unresectable HCC in comparison with TACE combined with RFA. We retrospectively analyzed 70 patients with HCC which was difficult to control by surgical resection or RFA monotherapy, 24 patients treated with PBT and 46 patients with TACE plus RFA. The therapeutic effects were assessed as local progression-free survival (PFS) and overall survival (OS). The local PFS was more than 65% in 60 months for PBT and TACE plus RFA. The patients treated with PBT showed 82% OS at 60 months post-treatment. In contrast, those treated with TACE plus RFA showed 28% OS. When comparing the changes of ALBI scores in patients with different severities of chronic liver disease, the scores of PBT-treated patients were maintained at the baseline; however, those of TACE plus RFA-treated patients worsened after the treatments. The results indicated that PBT may show better benefits than TACE plus RFA therapy in terms of OS in patients with unresectable HCC by sparing the non-tumor liver tissues.
Sections du résumé
BACKGROUND
Proton beam therapy (PBT) has been recently reported to achieve excellent tumor control with minimal toxicity in patients with unresectable hepatocellular carcinoma (HCC). Radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) was investigated for larger HCC. This study was designed to evaluate the therapeutic effect of PBT on unresectable HCC in comparison with TACE combined with RFA.
METHODS
We retrospectively analyzed 70 patients with HCC which was difficult to control by surgical resection or RFA monotherapy, 24 patients treated with PBT and 46 patients with TACE plus RFA. The therapeutic effects were assessed as local progression-free survival (PFS) and overall survival (OS).
RESULTS
The local PFS was more than 65% in 60 months for PBT and TACE plus RFA. The patients treated with PBT showed 82% OS at 60 months post-treatment. In contrast, those treated with TACE plus RFA showed 28% OS. When comparing the changes of ALBI scores in patients with different severities of chronic liver disease, the scores of PBT-treated patients were maintained at the baseline; however, those of TACE plus RFA-treated patients worsened after the treatments.
CONCLUSIONS
The results indicated that PBT may show better benefits than TACE plus RFA therapy in terms of OS in patients with unresectable HCC by sparing the non-tumor liver tissues.
Identifiants
pubmed: 37185409
pii: curroncol30040296
doi: 10.3390/curroncol30040296
pmc: PMC10136995
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3915-3926Références
J Gastroenterol. 2003;38(3):207-15
pubmed: 12673442
Radiat Oncol. 2013 Mar 05;8:48
pubmed: 23497543
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
J Clin Oncol. 2016 Feb 10;34(5):460-8
pubmed: 26668346
J Hepatol. 2021 Mar;74(3):603-612
pubmed: 33031846
Cancer. 2011 Jul 1;117(13):3053-9
pubmed: 21264826
J Gastrointest Oncol. 2020 Feb;11(1):157-165
pubmed: 32175119
Hepatol Res. 2020 Nov;50(11):1275-1283
pubmed: 32812315
Cancers (Basel). 2018 Feb 21;10(2):
pubmed: 29466294
Cancer Res Treat. 2015 Jan;47(1):34-45
pubmed: 25381830
BMC Cancer. 2019 Oct 22;19(1):983
pubmed: 31640620
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Liver Transpl. 2013 Feb;19(2):164-73
pubmed: 23008091
Dig Dis. 2017;35(6):602-610
pubmed: 29040999
Lancet. 2012 Mar 31;379(9822):1245-55
pubmed: 22353262
Int J Hyperthermia. 2022;39(1):455-465
pubmed: 35271786
J Hepatol. 2018 Jul;69(1):70-78
pubmed: 29524532
Hepatology. 2018 Aug;68(2):723-750
pubmed: 29624699
Acta Oncol. 2011 Aug;50(6):823-8
pubmed: 21767180
Int J Hyperthermia. 2022;39(1):1-7
pubmed: 34937501
Cancer Lett. 2016 Jan 1;370(1):78-84
pubmed: 26472630
Hepatology. 2021 Jan;73 Suppl 1:158-191
pubmed: 32430997
Cancers (Basel). 2018 Mar 14;10(3):
pubmed: 29538310
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Cancer. 2011 Nov 1;117(21):4890-904
pubmed: 21495022
Eur J Radiol. 2008 Aug;67(2):336-347
pubmed: 17765421
Liver Cancer. 2017 Nov;6(4):325-336
pubmed: 29234636
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):460-6
pubmed: 19427743
BMC Cancer. 2019 Aug 13;19(1):795
pubmed: 31409405
World J Gastroenterol. 2016 Feb 14;22(6):1935-42
pubmed: 26877601
Cancers (Basel). 2022 May 17;14(10):
pubmed: 35626073